Holy Name was the first hospital in the nation to offer monoclonal antibody therapy through clinical trials to patients at risk for severe complications from COVID-19.

Monoclonal antibody therapy actively disables the virus, preventing it from making patients seriously ill. The treatment is developed and manufactured in a lab based on antibodies provided by people who have recovered from COVID; it is not a blood product. The treatment is administered intravenously in the Medical Center’s COVID Infusion Center for those who are not hospitalized.

As the Omicron variant spreads, we have found that certain monoclonal antibody treatments are not effective for patients who become infected with this variant. There is one monoclonal antibody treatment that is currently effective against the Omicron variant.

If you currently have COVID-19 and are considered high-risk, Holy Name may be able to provide you with monoclonal antibodies treatment. In order to be evaluated for this treatment, please have your Holy Name provider refer you by contacting our North Jersey Telemedicine group at Covidinfusion@holyname.org or 201-833-3495.

At this time, we are only accepting referrals from providers affiliated with Holy Name. If you do not have a Holy Name physician, please find one here for an initial consultation.